The Immunology and Advanced CAR-T therapy, has laid the fundamental groundwork for genetically engineering patients’ immune T cells against their own cancer, based on the recognition and execution of cancer cells by cytotoxic T cells. This is done by adding a Chimeric Antigen Receptor (CAR) to the T cells to recognize the cancerous cells. CAR-T are white blood T cells outfitted with receptors that specifically seek out and identify tumors, promoting their destruction. This novel treatment combines the advantages of two immune system components: antibodies, which are capable of recognizing tumors but cannot efficiently penetrate them, and T cells, which -in principle- can carve through cancerous tissue, but often lack the ability to recognize and home in on the tumor. Over the course of two decades, CAR-T cell technology transformed from a revolutionary idea that works in the lab to a feasible treatment that is effective and safe in patients. Today, the FDA has approved this technology to treat leukemia and lymphoma patients. However, solid tumors are still a challenge, as well as manufacturing the CAR-T in a more productive way and developing an off-the-shelf CAR-T product. Our lab ‎is focused on producing many new CAR-T cells, with ‎specific recognition, or dual recognition to cancer cells, ‎as well as developing solutions for the current ‎challenges in this era.‎